CN104996986A - Food application of N-acetylneuraminic acid fermented from E. coli - Google Patents
Food application of N-acetylneuraminic acid fermented from E. coli Download PDFInfo
- Publication number
- CN104996986A CN104996986A CN201510406445.4A CN201510406445A CN104996986A CN 104996986 A CN104996986 A CN 104996986A CN 201510406445 A CN201510406445 A CN 201510406445A CN 104996986 A CN104996986 A CN 104996986A
- Authority
- CN
- China
- Prior art keywords
- acetyl
- neuraminate
- food
- escherichia coli
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 57
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 24
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title abstract description 11
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 title abstract description 9
- 239000000178 monomer Substances 0.000 claims abstract description 19
- UWBNZJVMKXMVFR-SGBOKBNOSA-N O.C(C)(=O)N[C@@H]1[C@H](CC(C(O)=O)(O)O[C@H]1[C@H](O)[C@H](O)CO)O Chemical compound O.C(C)(=O)N[C@@H]1[C@H](CC(C(O)=O)(O)O[C@H]1[C@H](O)[C@H](O)CO)O UWBNZJVMKXMVFR-SGBOKBNOSA-N 0.000 claims abstract description 7
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims description 66
- 238000000855 fermentation Methods 0.000 claims description 23
- 230000004151 fermentation Effects 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 235000008935 nutritious Nutrition 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013350 formula milk Nutrition 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 4
- 230000035764 nutrition Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000007844 bleaching agent Substances 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 238000004040 coloring Methods 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 235000010855 food raising agent Nutrition 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 230000037353 metabolic pathway Effects 0.000 abstract description 4
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 241000700605 Viruses Species 0.000 abstract 1
- 230000003988 neural development Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- ZUQUTHURQVDNKF-WZPXOXCRSA-N 1-[(3S,4R,5S,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethanone Chemical compound C(C)(=O)C1(O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO ZUQUTHURQVDNKF-WZPXOXCRSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001123 neurodevelopmental effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- -1 sialyl lactoses Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229930183912 Cytidylic acid Natural products 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- XLHZRMOOWTWQDE-SGBOKBNOSA-N OP(O)(O)=O.CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO Chemical compound OP(O)(O)=O.CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO XLHZRMOOWTWQDE-SGBOKBNOSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000005770 birds nest Nutrition 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a food application of N-acetylneuraminic acid fermented from E. coli. The N-acetylneuraminic acid exists in the form of N-acetylneuraminic acid monomer, N-acetylneuraminic acid hydrate or N-acetylneuraminic acid salt; the N-acetylneuraminic acid is safe and non-toxic, has a metabolic pathway in the human body by itself, and has the functions of involving in the cell membrane, resisting virus and promoting neural development.
Description
Technical field
The present invention relates to biochemical field and field of food, be specifically related to the application of N-acetyl-neuraminate in food in a kind of Escherichia coli fermentation source, the invention still further relates to the food formula combination comprising a kind of Escherichia coli fermentation source N-acetyl-neuraminate.
Technical background
The raising of domestic economy level makes government for health industry pay attention to day by day, and people are also more and more higher for the attention rate of own health, and except medical industries, basic food and derivative industry health products thereof have been a part for the daily demand of people all.
From nutrition angle, people's food composition becomes increasingly complex, and also press close to all the more self conscientiously to need, the component prescription as baby milk powder is more and more close with breast milk composition simultaneously, and usually edible nutrient prime replenisher also has corresponding scientific basis, reference per capita average daily intake is developed.In a word, day by day perfect along with healthy system, the absorption of nutritional labeling will more sophisticated, takes in form further natural.
N-acetyl-neuraminate is naturally occurring amino acid glucide, people are generally by egg, the N-acetyl-neuraminate of trace taken in by milk etc., a large amount of Research Literatures shows that this material has huge facilitation for the Antiviral Mechanism in human body brain development and body, but exist with the form of protein conjugates or carbohydrate bond because it is main in vivo, at field of food, now its application is still followed to the form of its derivative, as forms such as the sialyl lactoses in milk, in fact monomer whose has complete metabolic pathway in human body, this approach is also open by document, and N-acetyl-neuraminate monomer molecule amount only 309, it is the Small molecular very easily absorbed, can take in its simplest form completely, enzymatic conversion again in human body own metabolism approach is required multi-form.
As using the most universal bio-fermentation engineering, its productive prospecting is the high controllability of producing composition and operation, on this basis, the product simultaneously produced based on microorganism self, the natural attribute that obvious differences is originated in chemical industry, has possessed again the industrialization speciality being different from common agricultural source simultaneously: the large scale of construction, short period and high performance-price ratio.Therefore, we, at the N-acetyl-neuraminate monomer through long-time research and development Escherichia coli fermentation source, guarantee that highly purified N-acetyl-neuraminate monomer, salt or hydrate can be used to field of food.
The present invention is based on the monomer to N-acetyl-neuraminate, salt or hydrate (N-acetylneuraminic acid, N-acetylneuraminic acid hydrate, research and corresponding Study on Fermentation No. CAS: 131-48-6), be applied in food, as the nutritious supplementary pharmaceutical of the daily absorption of the mankind, there is raising immunity, promote the effects such as cranial nerve growth.
Summary of the invention
The N-acetyl-neuraminate that the object of the present invention is to provide a kind of Escherichia coli fermentation to originate, in the application of food, has raising immunity, promotes the effects such as cranial nerve growth.
The N-acetyl-neuraminate monomer in Escherichia coli fermentation source is only used to medicine intermediate at present.But study discovery through the present inventor, the N-acetyl-neuraminate in Escherichia coli fermentation source exists with the form of N-acetyl-neuraminate monomer, N-acetyl-neuraminate hydrate or N-acetyl-neuraminate salt, all can directly eat.
Therefore one object of the present invention is with the application of N-acetyl-neuraminate in food in Escherichia coli fermentation source.
According to a preferred embodiment of the present invention, described food is: health food, health medicine or nutritious supplementary pharmaceutical, and described nutritious supplementary pharmaceutical includes but not limited to formula milk, and solid-state or liquid form made by above-mentioned food.
According in the preferred embodiment of the present invention, the use content of described N-acetyl-neuraminate accounts for 0.01% ~ 60% of food total amount.
Find according to the present invention, N-acetyl-neuraminate is directly used in edible, and therefore, another object of the present invention, the invention provides a kind of food compositions, and described food compositions contains N-acetyl-neuraminate, and field of food can accept auxiliary material.
Described food can accept auxiliary material: thickener, stabilizing agent, emulsifying agent, antioxidant, color stabilizer, metal chelating agent, nutrition fortifier, anticorrisive agent, colouring agent, bleaching agent, leavening agent, acidity regulator, texturizing agents, anticaking agent, enzyme preparation, flavoring agent are or/and flavorant.
According to a preferred embodiment of the present invention, described food compositions is nutrient solution or nutrient tablet.These forms are prepared by method well known to those skilled in the art.
According to of the present invention one preferred embodiment, described N-acetyl-neuraminate accounts for 0.01% ~ 60% of above-mentioned food compositions gross weight.In a preferred embodiment, described N-acetyl-neuraminate accounts for 0.1% ~ 30% of described food compositions gross weight, and more preferably 0.5% ~ 20%, most preferably 5% ~ 15%.
N-acetyl-neuraminate of the present invention is obtained by Escherichia coli fermentation, finally obtains highly purified N-acetyl-neuraminate monomer dry powder or N-acetyl-neuraminate hydrate crystal by crystallization, or obtains N-acetyl-neuraminate salt through neutralization reaction.
According to a preferred embodiment of the present invention, appropriate vehicle is mainly water, comprises distilled water or deionized water.
N-acetyl-neuraminate monomer is natural to be present in human body cell, is combined with protein and carbohydrate, participates in cell membrane function, has antiviral and promotes neurodevelopmental function.
Detailed description of the invention
Unless otherwise defined, all technology used herein and scientific terminology have the identical meanings that one skilled in the art of the present invention understand jointly.Although or any method that be equal to similar with described herein and material can be used for implementing or testing the present invention, described herein is preferred method and material.For object of the present invention, define following term below.
Term " about " used herein refers to and the quantity of reference product, level, numerical value, dimension, size or amount ratio, difference can up to 30%, 20% or 10% quantity, level, numerical value, dimension, size or consumption.
In full section description and claims, Unless Otherwise Requested, following word " comprises " and its variant " contains " and " comprising " is interpreted as meaning to comprise described entirety or step, or one group of overall or step, but does not get rid of other overall or step any.
According to the present invention, term " N-acetyl-neuraminate " exists with the form of N-acetyl-neuraminate monomer, N-acetyl-neuraminate hydrate, N-acetyl-neuraminate salt.Term " N-acetyl-neuraminate hydrate " refers to the bond of N-acetyl-neuraminate monomer containing any amount crystallization water and hydrone, and term " N-acetyl-neuraminate salt " refers to that N-acetyl-neuraminate monomer ion and monovalence or polyvalent metal ion form the salt of covalent bond or form the complex compound of coordinate bond.Term " Escherichia coli fermentation source N-acetyl-neuraminate " refers to and directly obtains N-acetyl-neuraminate by Escherichia coli fermentation or refer to obtain poly sialic acid by Escherichia coli fermentation, obtains N-acetyl-neuraminate by hydrolysis or enzymolysis processing.
According to the present invention, term " food " comprises health food, health medicine or nutritious supplementary pharmaceutical, and described nutritious supplementary pharmaceutical includes but not limited to formula milk, and solid-state or liquid form made by above-mentioned food.
Present invention also offers a kind of food compositions, it is characterized in that, described food compositions contains N-acetyl-neuraminate and the receptible auxiliary material of field of food.Described " the receptible auxiliary material of field of food " can be selected from: thickener, stabilizing agent, emulsifying agent, antioxidant, color stabilizer, metal chelating agent, nutrition fortifier, anticorrisive agent, colouring agent, bleaching agent, leavening agent, acidity regulator, texturizing agents, anticaking agent, enzyme preparation, flavoring agent are or/and flavorant.
In a preferred embodiment in accordance with the present invention, described food compositions is health food, health medicine or nutritious supplementary pharmaceutical, and described nutritious supplementary pharmaceutical is formula milk, and solid-state or liquid form made by above-mentioned food.These forms of food compositions are prepared by method well known to those skilled in the art.
The working concentration of N-acetyl-neuraminate is 0.1mg/ml to 600mg/ml.Such as, the working concentration of N-acetyl-neuraminate can be 1mg/ml to 300mg/ml, preferred 5mg/ml to 200mg/ml.If add in food as additive, with the total weight of food compositions, described food compositions can comprise 0.01-60%N-n acetylneuraminic acid n.In the present invention one preferred embodiment, described N-acetyl-neuraminate accounts for the 5-15% of described composition total weight.
N-acetyl-neuraminate be extensively present in occurring in nature, be mainly combined on animal and plant cells memebrane protein, what wherein content was the highest is bird's nest.At present, the application for N-acetyl-neuraminate, salt or hydrate is mainly limited to medicine intermediate, is then blank out to the application of food.For looking for of known references and correlative study, and find no and relate to the application in food of N-acetyl-neuraminate, salt or hydrate and related efficacy.Therefore, the present invention proposes N-acetyl-neuraminate first and has participation cell membrane function, has antiviral and promotes neurodevelopmental function, can be used as nutritious supplementary pharmaceutical and add in food.
According to a preferred embodiment of the present invention, appropriate vehicle is mainly water (comprising distilled water, deionized water).
The present invention is set forth further below in conjunction with specific embodiment.But these embodiments, only for illustration of the present invention, do not form limitation of the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually conveniently condition, or advise condition according to manufacturer.Except as otherwise noted, all percentage and number are by mass.The 95% purity sample that in all embodiments, N-acetyl-neuraminate monomer sample provides by Wuhan Zhongke Guanggu Green Biological Technology Co., Ltd. below.
Embodiment 1: acute oral toxicological experiment
1.1 experimental technique
Compound concentration is the N-acetyl-neuraminate test liquid of 125mg/ml, experimental animal is 20 Kunming mouses, is divided into administration group and blank group at random, often organizes each 10, male and female half and half, the dosage once-a-day administration of 40ml/kg body weight is pressed in fasting respectively after 12 hours.Administration group and blank group respectively gavage give above-mentioned for reagent thing and purified water.Administration group adopts method of once limiting the quantity, and in one day, accumulated dose is 5000mg/kg.To observe after administration survival condition in instant toxic reaction and fortnight.
1.2 experimental results and conclusion
Toxic reaction and survival condition: after administration 10 minutes, the activity of administration group mouse reduces, and movablely after 30 minutes recovers normal; Within the fortnight observation period, have no time delay toxic reaction, animal is in good condition, and body weight increases, whole mouse survival.
N-acetyl-neuraminate monomer is on the impact of Mouse Weight (g)
Embodiment 2:N-n acetylneuraminic acid n monomer passway of metabolism
According to " Lehninger principles of biochemistry " (2005,4th edition, the work such as W.H Freeman), " Metabolism at a glance " (2004, the third edition, the work such as Alden) in cell, there is complete metabolic pathway in N-acetyl-neuraminate monomer (N-acetylneuraminic acid) described in book, namely after Cell uptake monomer under normal circumstances needed for vital metabolic.
N-acetyl-neuraminate is in intracellular three metabolic pathways:
1.N-n acetylneuraminic acid n and cytimidine triphosphoric acid generate cytimidine monophosphate N-acetyl-neuraminate and bis phosphoric acid radical ion through the effect of sialic acid cytidylic acid transferase, and this approach is reversible.
2.N-n acetylneuraminic acid n generates acetylmannosamine and pyruvic acid through acetylneuraminate lyase effect, and acetylmannosamine and PEP can synthesize N-acetyl-neuraminate again through sialic acid synthetase effect.
3. acetylmannosamine generates N-acetyl-D-MANNOSE amine-6-phosphoric acid through acetylmannosamine kinase effect, generate N-acetyl-neuraminate-9-phosphoric acid through sialic acid synthetase effect again, under magnesium ion existence condition, generate N-acetyl-neuraminate finally by N-acetyl-neuraminate phosphatase.
Claims (10)
1. the application of N-acetyl-neuraminate in food in an Escherichia coli fermentation source.
2. as claimed in claim 1 Escherichia coli fermentation source the application of N-acetyl-neuraminate in food, it is characterized in that: described N-acetyl-neuraminate exists with the form of N-acetyl-neuraminate monomer, N-acetyl-neuraminate hydrate or N-acetyl-neuraminate salt.
3. as claimed in claim 1 Escherichia coli fermentation source the application of N-acetyl-neuraminate in food, it is characterized in that: described food is health food, health medicine or nutritious supplementary pharmaceutical, and solid-state or liquid form made by food.
4. as claimed in claim 1 Escherichia coli fermentation source the application of N-acetyl-neuraminate in food, it is characterized in that: described nutritious supplementary pharmaceutical is formula milk.
5. as claimed in claim 1 Escherichia coli fermentation source the application of N-acetyl-neuraminate in food, it is characterized in that: described food also comprises the receptible auxiliary material of field of food.
6. as claimed in claim 5 Escherichia coli fermentation source the application of N-acetyl-neuraminate in food, it is characterized in that: the receptible auxiliary material of described field of food is: thickener, stabilizing agent, emulsifying agent, antioxidant, color stabilizer, metal chelating agent, nutrition fortifier, anticorrisive agent, colouring agent, bleaching agent, leavening agent, acidity regulator, texturizing agents, anticaking agent, enzyme preparation, flavoring agent are or/and flavorant.
7. as claimed in claim 1 Escherichia coli fermentation source the application of N-acetyl-neuraminate in food, it is characterized in that: the final utilization concentration of described N-acetyl-neuraminate in arbitrary food is 0.1mg/ml ~ 600mg/ml.
8. as claimed in claim 7 Escherichia coli fermentation source the application of N-acetyl-neuraminate in food, it is characterized in that: the final utilization concentration of described N-acetyl-neuraminate in arbitrary food is any concentration of 1mg/ml ~ 300mg/ml.
9. the application of N-acetyl-neuraminate in food of large Escherichia coli fermentable sources as claimed in claim 8, is characterized in that: the final utilization concentration of described N-acetyl-neuraminate in arbitrary food is any concentration of 5mg/ml ~ 200mg/ml.
10. as claimed in claim 9 Escherichia coli fermentation source the application of N-acetyl-neuraminate in food, it is characterized in that: the final utilization concentration of described N-acetyl-neuraminate in arbitrary food auxiliary material is any concentration of 50mg/ml ~ 150mg/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510406445.4A CN104996986A (en) | 2015-07-10 | 2015-07-10 | Food application of N-acetylneuraminic acid fermented from E. coli |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510406445.4A CN104996986A (en) | 2015-07-10 | 2015-07-10 | Food application of N-acetylneuraminic acid fermented from E. coli |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104996986A true CN104996986A (en) | 2015-10-28 |
Family
ID=54370077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510406445.4A Pending CN104996986A (en) | 2015-07-10 | 2015-07-10 | Food application of N-acetylneuraminic acid fermented from E. coli |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104996986A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS644961A (en) * | 1987-06-26 | 1989-01-10 | Matsushita Electric Ind Co Ltd | Floppy disk device |
| WO2011086834A1 (en) * | 2010-01-15 | 2011-07-21 | 味の素株式会社 | Process for production of n-acetyl-d-neuraminic acid |
| CN102946728A (en) * | 2010-03-12 | 2013-02-27 | 帝斯曼知识产权资产管理有限公司 | Maternal sialic acid supplementation |
| CN103284156A (en) * | 2013-06-20 | 2013-09-11 | 上海西宝生物科技有限公司 | Healthcare product composition and application thereof |
| CN103923869A (en) * | 2014-03-19 | 2014-07-16 | 武汉中科光谷绿色生物技术有限公司 | Bacillus subtilis gene engineering bacterial producing Neu5Ac, construction method and application thereof |
| CN104628794A (en) * | 2015-03-10 | 2015-05-20 | 武汉中科光谷绿色生物技术有限公司 | Method for separating and purifying N-acetylneuraminic acid produced by microbiological fermentation |
-
2015
- 2015-07-10 CN CN201510406445.4A patent/CN104996986A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS644961A (en) * | 1987-06-26 | 1989-01-10 | Matsushita Electric Ind Co Ltd | Floppy disk device |
| WO2011086834A1 (en) * | 2010-01-15 | 2011-07-21 | 味の素株式会社 | Process for production of n-acetyl-d-neuraminic acid |
| CN102946728A (en) * | 2010-03-12 | 2013-02-27 | 帝斯曼知识产权资产管理有限公司 | Maternal sialic acid supplementation |
| CN103284156A (en) * | 2013-06-20 | 2013-09-11 | 上海西宝生物科技有限公司 | Healthcare product composition and application thereof |
| CN103923869A (en) * | 2014-03-19 | 2014-07-16 | 武汉中科光谷绿色生物技术有限公司 | Bacillus subtilis gene engineering bacterial producing Neu5Ac, construction method and application thereof |
| CN104628794A (en) * | 2015-03-10 | 2015-05-20 | 武汉中科光谷绿色生物技术有限公司 | Method for separating and purifying N-acetylneuraminic acid produced by microbiological fermentation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Perna et al. | The role of glutamine in the complex interaction between gut microbiota and health: a narrative review | |
| Fergus et al. | The queuine micronutrient: charting a course from microbe to man | |
| Awad et al. | Intestinal structure and function of broiler chickens on diets supplemented with a synbiotic containing Enterococcus faecium and oligosaccharides | |
| Wurtman | A nutrient combination that can affect synapse formation | |
| Maru et al. | Calcium, magnesium, iron, zinc and copper, compositions of human milk from populations with cereal and ‘enset’based diets | |
| El-Desoky et al. | Effects of a nanoencapsulated moringa leaf ethanolic extract on the physiology, metabolism and reproductive performance of rabbit does during summer | |
| CN107949396A (en) | Alimentation composition comprising caseinhydrolysate | |
| CN104073463A (en) | Serum-free protein-free culture medium supporting CHO (Chinese Hamster Ovary Cell) high density suspension culture | |
| CN103796534A (en) | Use of a nucleotide for improving the heat stability of an aqueous micellar casein composition | |
| Zumreoglu-Karan et al. | Boric acid: a simple molecule of physiologic, therapeutic and prebiotic significance | |
| CN102335138A (en) | Preparation method of nano-composite vitamin with anti-stimulation action and livestock universality | |
| Chen et al. | Anti-fatigue effect of a dietary supplement from the fermented by-products of Taiwan tilapia aquatic waste and Monostroma nitidum oligosaccharide complex | |
| CN104982943A (en) | Application of N-acetylneuraminic acid sourced from fermentation of bacillus subtilis in food | |
| EP3266310A1 (en) | Nucleotide composition and application in food thereof | |
| CN103783290A (en) | High-efficiency feed additive capable of reducing cholesterol of bird eggs and preparation method thereof | |
| CN104996986A (en) | Food application of N-acetylneuraminic acid fermented from E. coli | |
| Juśkiewicz et al. | Influence of supplementation of lactoferrin, melittin and cecropin a to rat diet on changes in faecal ammonia concentrations, short-chain fatty acid concentrations and activities of bacterial enzymes | |
| CN102286386B (en) | Issatchenkia orientalis and method for producing citicoline by whole cell conversion of Issatchenkia orientalis | |
| CN105578901A (en) | Liquids and foodstuffs containing beta-hydroxy-beta-methylbutyrate (hmb) in free acid form | |
| CN103652369A (en) | General-purpose livestock nano nutritional agent having anti-stress function and preparation method of the nutritional agent | |
| CN105077280A (en) | Liquid preparation for supplementing zinc and preparation method thereof | |
| CN103053807B (en) | Water-soluble composite vitamin preparation and preparation method thereof | |
| CN104586862A (en) | Application of N-acetylneuraminic acid monomer, N-acetylneuraminic acid hydrate or N-acetylneuraminate in external anti-inflammation medicines | |
| Chen et al. | The Effect of Forage Source and Concentrated Liquid Feedstuff Supplementation on Improving the Synchronization of Ruminant Dietary Energy and Nitrogen Release In Vitro | |
| CN114601172A (en) | Formula food of glutamine composition with special medical application and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151028 |
|
| RJ01 | Rejection of invention patent application after publication |